Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
GRP | Does anyone have an idea when the Listing Date is | 08/02/16 | 3 | 2.4K | |||
|
|||||||
GRP | Ann: Appendix 3B | 06/01/16 | 0 | 688 | |||
|
|||||||
GRP | well over subscribed | 04/01/16 | 9 | 5.4K | |||
|
|||||||
GRP | Ann: Prospectus Closed Over Subscribed | 24/12/15 | 0 | 704 | |||
|
|||||||
GRP | Ann: EXTENSION OF AUTOMATIC REMOVAL OF LONG TERM SUSPENDED ENTITY | 18/12/15 | 0 | 820 | |||
|
|||||||
GRP | Ann: Appendix 3B | 18/12/15 | 0 | 696 | |||
|
|||||||
GRP | Ann: Prospectus | 14/12/15 | 0 | 875 | |||
|
|||||||
GRP | Ann: Results of Meeting | 09/12/15 | 3 | 1.9K | |||
|
See All Discussions